The PRC2-dependent epigenetic reprograming of the bladder epithelium exacerbates urinary tract infections

Mucosal imprint sensitizes recurrent urinary tract infections (UTIs), a significant health and quality of life burden worldwide, which are associated with heightened inflammatory host response, severe basal cell hyperplasia and impaired superficial cell differentiation. Here, we show that bladder infections induce expression of Ezh2, the methyltransferase of polycomb repressor complex 2 (PRC2)-dependent epigenetic gene silencing program. In mouse models of UTIs, urothelium-specific inactivation of PRC2 reduces the urine bacteria burden. The mutants exhibit a blunted inflammatory response likely due to the diminished activity of NF-{kappa}B signaling pathway. PRC2 inactivation also improves urothelial differentiation and attenuates basal cell hyperplasia phenotype. Moreover, the Ezh2-specific small molecule inhibitors markedly improve disease outcomes of bladder superinfection and chronic cystitis. Taken together, these findings suggest that the UTI-induced epigenetic reprograming in the bladder urothelium likely contributes to the mucosal imprint, and further suggest that targeting PRC2 methyltransferase offers a non-antibiotic strategy to mitigate UTIs.